Quote:

---

However, I am not sure if Leronlimab would cause brain swelling and brain bleeding. That appears to be the desired side effect.

---

Interesting question. Donanemab, aduhelm and recently approved lecanemab all bind to amyloid beta deposits causing microglia to destroy them through phagocytosis. Those drugs cause the ab deposits to be targeted by microglia. Overactive microglia is a hallmark of Alzheimer's and Huntington's but their must be a factor that causes them to ignore ab deposits. It may be similar to how cancer tumors use the immune system to protect themselves. That process almost certainly causes a higher level of inflammation which may result in brain bleed. Overactive microglia can also cause damage to surrounding neurons.

There is also nothing in those drugs that would curb pro-inflammatory cytokines that are an underlying cause of neuronal damage. Inflammation causes overactive microglia and the microglia further increases inflammation. Donanemab and lecanemab will have affect against ab deposits but do nothing for the underlying pathology.

Leronlimab uses autophagosomes to degrade amyloid beta deposits. As important it downregulates inflammatory factors like NLRP3, mTORC1, TNF-a , NF-kb, IL-18 and IL-1b which are associated with Alzheimer's and Huntington's disease. Given the control of inflammation and balancing of microglia activation brain bleed would be much less likely to occur.